Predicting Chemotherapy Response in Ovarian Cancer
Author Information
Author(s): Chiara Arienti, Anna Tesei, Giorgio Maria Verdecchia, Massimo Framarini, Salvatore Virzì, Antonio Grassi, Emanuela Scarpi, Livia Turci, Rosella Silvestrini, Dino Amadori, Wainer Zoli
Primary Institution: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)
Hypothesis
Can conventional chemosensitivity tests and biomolecular markers predict response to platinum-based chemotherapy in patients with peritoneal carcinomatosis from ovarian cancer?
Conclusion
The in vitro chemosensitivity test is more effective in predicting chemotherapy response than biomolecular markers alone.
Supporting Evidence
- MGMT and XPD expression levels were significantly related to resistance to platinum treatment.
- The in vitro chemosensitivity test showed 85.7% sensitivity and 91.3% resistance predictivity.
- High predictivity of resistance was observed for XPD, but low predictivity for sensitivity.
Takeaway
Doctors can use a lab test to see how well cancer drugs will work for patients with ovarian cancer, which helps them choose the best treatment.
Methodology
The study involved fresh surgical biopsy specimens from 30 patients, analyzing gene expression and conducting an in vitro chemosensitivity test.
Limitations
The study was limited by the small sample size and the inability to perform tests on two patients due to insufficient material.
Participant Demographics
Median age of patients was 60 years, with a range of 32-81 years; all had serous tumor subtypes.
Statistical Information
P-Value
0.0003
Confidence Interval
95% CI 0.53-0.94
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website